Has Jikkuu Zachariah, DO received payments from drug or device companies?

Yes. Drug and device makers reported $294,573 in general payments to Jikkuu Zachariah, DO across 242 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jikkuu Zachariah, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jikkuu Zachariah, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jikkuu Zachariah, DO

Neurology · Reading, PANPI 1336597707

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $184,666 of the $294,573 with a category attached, or 62.7%. 16 manufacturers reported payments, led by EMD Serono, Inc. at 36.5% of the total. 2025 is the largest year on record at $110,415, more than ten times the $692 reported in 2019. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$294,573in general payments, 2019–2025

Across 242 payments — averaging $1217.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

EMD Serono, Inc.$108K
Biogen$88K
TG Therapeutics, Inc.$46K
Sanofi$34K
E.r. Squibb & Sons, L.L.C.$15K
Bristol Myers Squibb$2K
plus $2K from 10 others

$117,931in research payments, 2019–2025

Across 8 payments — averaging $14,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$65K
Sanofi$53K

What the payments were for

Consulting fees$1,4901%
Speaking & faculty fees$184,66663%
Grants$87,75030%
Travel & lodging$12,7974%
Food & beverage$7,5033%
Education$3670%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
EMD Serono, Inc.	74	$107,573
Biogen	7	$88,079
TG Therapeutics, Inc.	47	$45,590
Sanofi	17	$34,453
E.r. Squibb & Sons, L.L.C.	22	$14,945
Bristol Myers Squibb	34	$2,153
Genentech, Inc.	8	$362
Genentech USA, Inc.	4	$259
AstraZeneca	2	$246
Novartis	7	$230
Johnson & Johnson	3	$209
AbbVie	10	$179
Sanofi-aventis U.S. LLC	3	$169
Lilly USA, LLC	2	$85
UCB, Inc.	1	$21
Amgen	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Mavenclad$68,044
BRIUMVI$44,750
ZEPOSIA$14,888
OCREVUS$235
Vumerity$122
SOLIRIS$121
KESIMPTA$120
AUBAGIO$114

How this compares

$294,573 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$15,624

Medicare patients

Services billed

234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AubagioTeriflunomide	16	$213,523
Kesimpta PenOfatumumab	15	$133,843
VumerityDiroximel Fumarate	12	$105,668
CopaxoneGlatiramer Acetate	11	$63,062
Dalfampridine ErDalfampridine	40	$9,834
Dimethyl Fumarate	17	$4,008
Teriflunomide	35	$1,841
Gabapentin	59	$1,588
Baclofen	56	$1,408
Carbamazepine	12	$787
Tizanidine Hcl	20	$659
Ropinirole Hcl	19	$460
Donepezil Hcl	17	$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
SanofiAubagio	$34,453	$213,52316 claims
BiogenVumerity	$88,079	$105,66812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.